In the Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT) study, patients at high risk of traumatic complications after percutaneous coronary intervention were randomized after three months of dual anti-platelet therapy (DAPT) to either ticagrelor and aspirin or ticagrelor alone.

Mayo Clinic interventional cardiologist Patricia J. Best, M.D., discusses the TWILIGHT study in this video first shown on Medscape Cardiology.

Explore more Mayo Clinic Cardiovascular Medicine Resources for Medical Professionals.